• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MedinCell to begin regulatory development of long-acting injectable malaria treatment

June 15, 2021 By Sean Whooley

MedinCellMedinCell announced that its long-acting injectable malaria treatment is ready to enter into the stages of regulatory development.

Montpellier, France–based MedinCell conducted an in vivo proof of concept on cattle that demonstrated three-month mosquitocidal effectiveness in the injectable, long-acting formulation of Ivermectin using the company’s BEPO delivery technology.

The company designed the investigational mdc-STM product to reduce the transmission of the parasite responsible for Malaria through a killing effect on the vector mosquitoes when they bite treated people, according to a news release.

BEPO technology offers control over regular drug delivery at the optimal therapeutic dose for several days, weeks or months, beginning with the subcutaneous or local injection of a simple deposit of a few millimeters. In addition, it is fully bioresorbable, the company says.

MedinCell in March 2020 received a $6.4 million subvention over three years from global health agency Unitaid to conduct the formulation and preclinical activities for the malaria treatment.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials, Research & Development Tagged With: MedinCell

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS